Article · 30 Apr 2025
OtherPublished 21 Jul 2016
Eliglustat tartrate: an oral therapeutic option for Gaucher disease type 1
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Gaucher disease is an inborn error of glycosphingolipid catabolism, which has been shown to be responsive to enzyme replacement therapy and substrate synthesis inhibition. Eliglustat tartrate, an analog of D-threo-1-phenyl-2-decanoylamino-3-morpholino-propanol, is an orally administered agent with properties of substrate synthesis inhibition and an acceptable pharmacokinetic profile. In Phase II clinical trials (both in the published pivotal and extension phase), eliglustat was shown to have a favorable, safe and efficacious profile. Three additional studies – identified by the acronyms ENCORE, ENGAGE and EDGE – are ongoing; it is anticipated these trials will provide additional information leading to regulatory approval. In addition, insights from these trials are expected to facilitate the development of therapeutic guidelines for the management of patients with Gaucher disease, incorporating eliglustat into the expanding list of therapeutic options.
Subjects
General & Internal MedicineAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Clinical Investigation.
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalClinical Investigation
- SubjectGeneral & Internal Medicine
- BylineArticles whose byline prints “Gregory M Pastores”
- BylineArticles whose byline prints “Derralynn Hughes”